Passiflora for anxiety disorder
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anxiety is a very common mental health problem in the general population and in the primary care setting. Herbal medicines are popularly used worldwide and could be an option for treating anxiety if shown to be effective and safe. Passiflora (passionflower extract) is one of these compounds. OBJECTIVES: To investigate the effectiveness and safety of passiflora for treating any anxiety disorder. SEARCH STRATEGY: The following sources were used: electronic databases: Cochrane Collaboration Depression, Anxiety and Neurosis Cochrane Controlled Trials Register (CCDANCTR-Studies), Medline and Lilacs; Cross-checking references; contact with authors of included studies and manufacturers of passiflora. SELECTION CRITERIA: Relevant randomised and quasi-randomised controlled trials of passiflora using any dose, regime, or method of administration for people with any primary diagnosis of general anxiety disorder, anxiety neurosis, chronic anxiety status or any other mental health disorder in which anxiety is a core symptom (panic disorder, obsessive compulsive disorder, social phobia, agoraphobia, other types of phobia, postraumatic stress disorder). Effectiveness was measured using clinical outcome measures such as Hamilton Anxiety Scale (HAM-A) and other scales for anxiety symptoms. DATA COLLECTION AND ANALYSIS: Two reviewers independently selected the trials found through the search strategy, extracted data, performed the trial quality analyses and entered data. Where any disagreements occured, the third reviewer was consulted. Methodological quality of the trials included in this review was assessed using the criteria described in the Cochrane Handbook. For dichotomous outcomes, relative risk with 95% confidence intervals (CI) were calculated, and for continuous outcomes, weighted mean difference with 95%CI was used. MAIN RESULTS: Two studies, with a total of 198 participants, were eligible for inclusion in this review. Based on one study, a lack of difference in the efficacy of benzodiazepines and passiflora was indicated. Dropout rates were similar between the two interventions. Although the findings from one study suggested an improvement in job performance in favour of passiflora (post-hoc outcome) and one study showed a lower rate of drowsiness as a side effect with passiflora as compared with mexazolam, neither of these findings reached statistical significance. AUTHORS' CONCLUSIONS: RCTs examining the effectiveness of passiflora for anxiety are too few in number to permit any conclusions to be drawn. RCTs with larger samples that compare the effectiveness of passiflora with placebo and other types of medication, including antidepressants, are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bijl, R. V., Ravelli, A., & van Zessen, G. (1998) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s001270050098 · Cited by 1,216
Quality of Life in Individuals With Anxiety Disorders
Mendlowicz, M. V., & Stein, M. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.669 · Cited by 955
Borkovec, T. D., & Costello, E. (1993) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.61.4.611 · Cited by 756
Gould, R. A., Otto, M. W., Pollack, M. H., & Yap, L. (1997) · Behavior Therapy · doi:10.1016/s0005-7894(97)80048-2 · Cited by 352
Research works printed but not linked: 20
- Akhondzadeh, 2001, Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam, Journal of Clinical Pharmacy and Therapeutics, 26, 363, 10.1046/j.1365-2710.2001.00367.x · DOI · Paper page
- Mori, 1993, Clinical Evaluation of Passiflamin (passiflora extract) on neurosis - multicenter double blind study in comparison with mexazolam, Clinical Evaluation, 21, 383
- Bourin, 1997, A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: controlled study versus placebo, Fundamental & Clinical Pharmacology, 11, 127, 10.1111/j.1472-8206.1997.tb00179.x · DOI · Paper page
- Almeida-Filho, 1997, Brazilian multicentric study of psychiatric morbidity. Methodological features and prevalence estimates, British Journal of Psychiatry, 171, 524, 10.1192/bjp.171.6.524 · DOI · Paper page
- Borkovec, 1987, The effects of relaxation training with cognitive or nondirective therapy and the role of relaxation-induced anxiety in the treatment of generalized anxiety disorder, Journal of Consulting & Clinical Psychology, 55, 883, 10.1037/0022-006X.55.6.883 · DOI
- Clarke, 2000, Cochrane Collaboration Handbook
- Fisher, 2000, Toxicity of Passiflora incarnata, Clinical Toxicology, 38, 63, 10.3109/15563650.2013.870343 · doi:10.3109/15563650.2013.870343
- Hamilton, 1959, The assessment of anxiety states by rating, British Journal of Medical Psychology, 32, 50, 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
- Hunot, 2006, Psychological therapies for generalised anxiety disorder [Psychotherapy for generalized anxiety disorder], Cochrane Database of Systematic Reviews, 10.1002/14651858.CD001848.pub3 · DOI · Paper page
- Jadad, 1996, Assessing the quality of reports of randomised clinical trials: is blinding necessary?, Controlled Clinical Trials, 17, 1, 10.1016/0197-2456(95)00134-4 · DOI · Paper page
- Kessler, 1994, Lifetime and 12 month prevalence of DSM III R psychiatric disorders in the United States, Archives of General Psychiatry, 51, 8, 10.1001/archpsyc.1994.03950010008002 · DOI · Paper page
- Newall, 1996, Herbal medicines: a guide for health care professionals
- Olin, 1989, Passion Flower monograph
- Pitter, 2002, Kava extract for treating anxiety, Cochrane Database of Systematic Reviews
- Priest, 1988, Benzodiazepines and dependence: A college statement, Bulletin of the Royal College of Psychiatrists, 12, 107, 10.1192/pb.12.3.107 · DOI
- Rickels, 1993, Antidepressants for the treatment of generalized anxiety disorder: aplacebo controlled comparison of imipramine, trazodone and diazepam, Arch Gen Psychiatry, 50, 884, 10.1001/archpsyc.1993.01820230054005 · DOI · Paper page
- Schulz, 1995, Empirical evidence of bias: dimension of methodological quality associated with estimates of treatment effects in controlled trials, JAMA, 273, 408, 10.1001/jama.1995.03520290060030 · DOI
- Taylor, 1978, Relaxation training and related techniques In: Behavioral modifications: principles and clinical applications
- Taylor, 1988, The nature and the treatment of anxiety disorders
- Walley, 1994, Management of common anxiety disorders, American Family Physician, 50, 1745
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Cochrane meta-analyses found two studies of passiflora (passion flower) indicating it was as effective as benzodiazepines (Level 2) [633], and one study of valerian which found no significant differences between placebo, valerian, or diazepam (Level 2, negative) [634,635].”
BackgroundSarris, J., Panossian, A., Schweitzer, I., Stough, C., & Scholey, A. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.04.002 · Cited by 469
Traditional use and safety of herbal medicines1
Moreira, D. D. L., Teixeira, S. S., Monteiro, M. H. D., De-Oliveira, A. C. A. X., & Paumgartten, F. J. R. (2014) · Revista Brasileira de Farmacognosia · doi:10.1016/j.bjp.2014.03.006 · Cited by 266
Complementary Therapies for Mental Health Disorders
Asher, G. N., Gerkin, J., & Gaynes, B. N. (2017) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.04.004 · Cited by 93
Medicinal herbs for the treatment of anxiety: a systematic review and network meta-analysis
Zhang, W., Yan, Y., Wu, Y., Yang, H., Zhu, P., Yan, F., Zhao, R., Tian, P., Wang, T., Fan, Q., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106204 · Cited by 75
Metadata
- Authors
- Miyasaka, L. S., Atallah, Á. N., & Soares, B.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2007-01-24
- Volume
- 2010
- Issue
- 1
- Pages
- CD004518-CD004518
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1586845255
- Cited by
- 78
- References
- 4
- FWCI
- 17.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.